Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Communications • Medical Devices & Mechanical Engineering
6 pending office actions • 6 clients • 6 examiners • 4 art units • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cozen O'Connor-DC Office operates in the Biotechnology & Pharmaceuticals technology area, with 3 pending office actions currently active. This work is part of the firm's broader career history of 19375 applications. The 3 pending office actions represent the current focus for this specific set of files. The firm's experience in Biotechnology & Pharmaceuticals is supported by their 19375 career applications.
The firm maintains a resolved allowance rate of 85.65 percent, a figure calculated from their 19375 career applications. This 85.65 percent rate serves as a benchmark for the outcomes of their patent filings. Prosecution involves an average of 3.35 office actions per allowance, a metric that describes the typical interaction with patent examiners. For practitioners, this 3.35 average is a key indicator of the effort required to reach an allowance. The 3 pending office actions are managed alongside this 85.65 percent allowance rate and 3.35 office action average. These statistics provide a clear view of the firm's historical and current performance.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
| JANG, CHRISTIAN Y | 1 | 68.5% | +21.0% |
| HAYMAN, IMANI N | 1 | 71.6% | +25.4% |
| STIMPERT, PHILIP EARL | 1 | 63.1% | +48.8% |
| MUNION, JAMES E | 1 | 76.5% | +23.7% |
| HINES, JANA A | 1 | 53.0% | +39.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | NOAKES, SUZANNE MARIE | 66d overdue |
| 18561817 | DISINFECTION COMPOSITION | HINES, JANA A | 37d overdue |
| 18763135 | LIQUID MEDICINE INJECTION APPARATUS | HAYMAN, IMANI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | NOAKES, SUZANNE MARIE | 66d overdue |
| 18561817 | DISINFECTION COMPOSITION | HINES, JANA A | 37d overdue |
| 18846979 | METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME | JANG, CHRISTIAN Y | — |
| 18763135 | LIQUID MEDICINE INJECTION APPARATUS | HAYMAN, IMANI N | — |
| 18759214 | NEEDLE ASSEMBLY AND LIQUID MEDICINE INJECTION APPARATUS COMPRISING SAME | STIMPERT, PHILIP EARL | — |
| 18750163 | DUAL-TECHNOLOGY ELECTRONIC SEAL WITH INTEGRITY MONITORING SYSTEM AND INTEGRITY MONITORING METHOD OF SAID SEAL | MUNION, JAMES E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Sun, Zhenglong | 1 |
| SUNGKWANG MEDICAL FOUNDATION | 1 |
| EOFLOW CO., LTD. | 1 |
| Ipv | 1 |
| Monitainer Tecnologia E Serviços Ltda | 1 |
| KDC/ONE | 1 |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 3796 | 1 |
| 2688 | 1 |
| 1645 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19069321 | SERINE PROTEASE FOR SELECTIVELY DEGRADING MUCINS AND USE THEREOF | Zhenglong Sun | NOAKES, SUZANNE MARIE | 1656 | §102§112 | Non-Final OA | 66d overdue | Pending | Mar 04, 2025 |
| 18846979 | METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME | Sungkwang Medical Foundation | JANG, CHRISTIAN Y | 3796 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18763135 | LIQUID MEDICINE INJECTION APPARATUS | Eoflow Co., Ltd. | HAYMAN, IMANI N | §102§112 | Non-Final OA | — | Pending | Jul 03, 2024 | |
| 18759214 | NEEDLE ASSEMBLY AND LIQUID MEDICINE INJECTION APPARATUS COMPRISING SAME | Ipv | STIMPERT, PHILIP EARL | §102 | Non-Final OA | — | Pending | Jun 28, 2024 | |
| 18750163 | DUAL-TECHNOLOGY ELECTRONIC SEAL WITH INTEGRITY MONITORING SYSTEM AND INTEGRITY MONITORING METHOD OF SAID SEAL | Monitainer Tecnologia E Serviços Ltda | MUNION, JAMES E | 2688 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18561817 | DISINFECTION COMPOSITION | ZOBELE HOLDING S.P.A. | HINES, JANA A | 1645 | §101§102§103 | Final Rejection | 37d overdue | Pending | Nov 17, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial